Sandeep Soni, MD

Sandeep Soni, MD is an Associate Professor of Pediatrics at The Ohio State University College of Medicine. He is an active member of American Society for Blood and Marrow Transplant, Pediatric Blood & Marrow Consortium and Hematopoietic Stem Cell Transplant Committee of Children’s Oncology Group. His research interests include myeloablative and non-myeloablative conditioning regimens for BMT and design of new BMT strategies for neuroblastoma and myeloid leukemias.

Gender:

• Male

Languages Spoken:

• English
• Hindi

Graduate School

• Maulana Azad Medical College University of New Del
  Date Completed: 12/31/1986

Internship

• Maulana Azad Medical College and Associated Hospit
  Date Completed: 12/31/1987

Internship

• Maulana Azad Medical College and Associated Hospit
  Date Completed: 06/30/1988

Residency

• Kalawati Saran Children's Hospital
  Date Completed: 06/30/1991

Residency

• Kalawati Saran Children's Hospital
  Date Completed: 07/31/1994

Fellowship

• Hadassah University Hospital
  Date Completed: 03/31/1997

Fellowship

• Albert Einstein Montefiore Medical Center
  Date Completed: 06/30/2000

Residency

• Montefiore Medical Ctr/Albert Einstein College of
  Date Completed: 06/30/2002

Fellowship

• University of Texas MD Anderson Cancer Center
  Date Completed: 08/31/2003

Department:

• Pediatrics

Section:

• Hematology/Oncology

Speciality:

• Pediatric Hematology Oncology
  

Date of Appointment at Nationwide Children’s Hospital:

• 09/29/2006

• M.A. Skeens, V. Pai, A. Garee, R. Bajwa, T. Gross, A. Termuhlen, S. Soni. 2010. Twice Daily Intravenous Tacrolimus (FK-506) Is A Safe And Effective Graft vs. Host Disease (GVHD) Prophylaxis For Pediatric Allogeneic Hematopoietic Stem Cell (HSCT) Recipients.  Biology of Blood and Marrow Transplantation. Vol. 16, no. 2. (February): eS328.
• S. Soni, M. Skeens, T.G. Gross, R.P. Bajwa, S.K. Baker, A. Termuhlen. 2010. Outcomes After Addition Of Rabbit-ATG To The Standard BU+CY Preparative Regimen For Allogeneic Matched Sibling Donor (MSD) Hematopoietic Stem Cell Transplantation (HSCT) For Hemoglobinopathies In Children.  Biology of Blood and Marrow Transplantation. Vol. 16, no. 2. (February): eS242.
• M.A. Skeens, S. Soni, V. Pai, R. Bajwa, D. Pietryga, T. Gross, A. Termuhlen. 2010. Case Control Study Of Levetiracetam Vs. Fosphenytoin For Seizure Prophylaxis In Children Receiving Busulfan (BU) For Hematopoietic Stem Cell Transplantation (HSCT).  Biology of Blood and Marrow Transplantation. Vol. 16, no. 2. (February): eS195.
• B Horn, S Soni, S Khan, A Petrovic, N Breslin, M Cowan, G Pelle Day, E Cooperstein, L-A Baxter Lowe. 2009. Feasibility Study of preemptive withdrawal of immunosuppression based on chimerism testing in children undergoing myeloablative allogeneic transplantation for hematologic malignancies.  Bone Marrow Transplantation. Vol. 43, no. 6. (March): 469-476.
• S. Soni, A. Termuhlen, R.P.S. Bajwa, J. Clayton, M. Montgomery, D. Hardin. 2009. Prevalence, Risk Factors andManagement of Metabolic Syndrome After Stem Cell Transplantation In Pediatric Patients.  Biology of Blood and Marrow Transplantation. Vol. 15, no. 2. (February): 80-81.
• Termuhlen AM, Klopfenstein K, Olshefski R, Rosselet R, Yeager ND, Soni S, Gross TG. 2008. Mobilization of PML-RARA negative blood stem cells and salvage with autologous peripheral blood stem cell transplantation in children with relapsed acute promyelocytic leukemia.  Pediatr Blood Cancer.. Vol. 51, no. 4. (October): 521-524.
• Soni S, Hente M, Breslin N, Hersh J, Whitley C, Cheerva A, Bertolone S. 2007. Pre-stem cell transplantation enzyme replacement therapy in Hurler syndrome does not lead to significant antibody formation or delayed recovery of the endogenous enzyme post-transplant: a case report.  Pediatric Transplantation. Vol. 11, no. 5. (January): 563-567.
• Soni S. 2007. Allogeneic Stem Cell Transplantation for genetic disorders.  Journal of the Kentucky Medical Association. Vol. 105, no. 1. (January): 8-12.
• Soni S, Lee D, Radel E, et.al. 2002. Treatment of Pediatric Ocular Melanoma with high dose Interleukin 2 and Thalidomide.  Journal of Pediatric Hematology and Oncology. Vol. 6, no. 24. (August): e488.
• Soni S, Radel E, Edelman M, et al. 2001. Squamous Cell Carcinoma of the tongue in a child- complete response to a Chemo-radiotherapy regimen.  Journal of Pediatric Hematology Oncology. Vol. 9, no. 23. (December): e612.
• H Horig, A Wainstein, Li Long, D Kahn, S Soni, R Kucheralapati, H Kaufman. 2001. A new mouse model for evaluating the immunotherpay of human colo-rectal cancer.  Cancer Research. Vol. 23, no. 61. (December): 8520-8526.
• Nagler A, Soni S, Samuel S, Or R. 1998. Engraftment following Mitoxantrone based conditioning for allogeneic BMT.  Leukemia Research. Vol. 3, no. March: 209-213.
• Soni S, Hente M, Breslin N, et.al. Pre-stem cell transplantation enzyme replacement therapy in Hurler syndrome does not lead to significant antibody formation or delayed recovery of the endogenous enzyme post-transplant: a case report. Pediatric Transplantation 11(5): 563-567, August 2007.
• Soni S. Allogeneic stem cell transplantation for genetic disorders. Journal KY Medical Association 105(1): 12-16, January 2007.